Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sylvant

- PMLiVE

Spinraza keeps Biogen buoyant ahead of Alzheimer’s data

Biotech sees 9% growth ahead of potential landmark announcement

- PMLiVE

Sanofi’s rare blood disorder drug Cablivi set for European approval

Rare disease drug among notable CHMP recommendations

- PMLiVE

Roche’s MabThera ends drug drought for serious skin disease

As biosimilars seize market share, Roche finds ways to extend blockbuster's revenues

- PMLiVE

Drugs for rare diseases will help propel pharma sales to $1.2trn by 2024; report

Orphan drug sales growth will be 11%+ a year

- PMLiVE

J&J moves quickly ahead with trials of myeloma CAR-T

Expects to start trials during the second half of this year

Janssen & Research Partnership win prestigious BHBIA Best Business Impact award

We are delighted to announce that Janssen and Research Partnership have won the BOBI (Best of Business Intelligence) Award in the Best Business Impact category at the BHBIA annual conference in London for our collaborative market research...

Research Partnership

- PMLiVE

Daily Brief: UK must follow through on Life Sciences Strategy, haemophilia gene therapy latest and more

A rapid round up from the frontline of pharma, biotech and healthcare

- PMLiVE

Despite FDA concerns, Akcea rare disease drug clears FDA panel

FDA now set to deliver final verdict by 30 August

- PMLiVE

Daily Brief: Deal done, Takeda to cut $1.4bn, Brexit latest, Valeant rebrands

A rapid round-up of the top pharma, biotech and healthcare news

- PMLiVE

Accelerating diagnosis in rare disease

Biopharmaceutical companies can drive effective partnerships and improve outcomes for all stakeholders and patients in the area of rare disease.

Research Partnership and Janssen are 2017-18 BOBI Awards finalists

We are delighted to announce that an entry submitted by Research Partnership with Janssen has been selected as a finalist in the Best Business Impact category at this year’s BOBI...

Research Partnership

- PMLiVE

Vivid Medical Communications Supports the 10th Anniversary of Rare Diseases Day 2018

Vivid Medical Communications – a newly created rare diseases specialist agency and part of the successful Lucid Group of companies – is a proud supporter of Rare Diseases Day 2018.

Lucid Group Communications Limited

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links